|Day Low/High||2.35 / 2.56|
|52 Wk Low/High||1.65 / 5.05|
North Korea puts a worrying wrinkle in the markets. We add to 2 portfolio positions.
Unless there is a dilution event around the corner, the selloff is overdone.
We'll purchase more shares of Pixelworks and Inovio ahead of their quarterly results next week.
We made several trades and price target changes during a mixed week for the portfolio.
Sometimes, changing the price target is better than selling (or buying).
The portfolio has some high fliers and underperformers last week as we head into the heart of earnings season.
Investors in AcelRx Pharmaceuticals Inc saw new options begin trading today, for the March 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 235 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
We brought a new name into the portfolio last week as the Fed's comments helped lift the market.
We made no trades during the holiday-shortened week, but added to our natural hedge today.
We added a name to the portfolio's Bullpen as a whirlwind quarter came to an end.
We exited 2 positions and took some profits during a busy week for the portfolio.
We initiated a new position and made several other trades during a week of twists and turns.
We initiated 2 new positions in a week dominated by political events.
We're buying a small position in Inovio Pharmaceuticals and downgrading AcelRx.
We scaled further into one position and added a Bullpen name as the market shrugged off geopolitical uncertainties.
It was a busy week of moves in the portfolio as we head into the latter half of the second quarter.
AcelRx Pharmaceuticals is another interesting, yet speculative, play.
The most recent short interest data was recently released for the 09/30/2016 settlement date, and AcelRx Pharmaceuticals Inc is one of the most shorted stocks of the Russell 3000, based on 8.72 "days to cover" versus the median component at 5.36. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.
AcelRx Pharmaceuticals (ACRX) announced on Thursday that ARX-04, its experimental pain relief drug, had positive results in a phase III clinical trial.
Investors in AcelRx Pharmaceuticals Inc saw new options begin trading this week, for the September 16th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 233 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a weak on high relative volume candidate
Trade-Ideas LLC identified AcelRx Pharmaceuticals (ACRX) as a strong on high relative volume candidate
There's a valuable, albeit painful, lesson here in Amicus' blow-up. Biotech CEOs should shut their mouths about regulatory plans until they receive definitive word from the FDA.
These stocks look ready to break out and trade higher from current levels.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.